WO2001028543A1 - TREATMENT OF EOSINOPHIL ASSOCIATED PATHOLOGIES BY MODULATING PKC-δ ACTIVITY - Google Patents

TREATMENT OF EOSINOPHIL ASSOCIATED PATHOLOGIES BY MODULATING PKC-δ ACTIVITY Download PDF

Info

Publication number
WO2001028543A1
WO2001028543A1 PCT/US2000/027277 US0027277W WO0128543A1 WO 2001028543 A1 WO2001028543 A1 WO 2001028543A1 US 0027277 W US0027277 W US 0027277W WO 0128543 A1 WO0128543 A1 WO 0128543A1
Authority
WO
WIPO (PCT)
Prior art keywords
pkcδ
agent
activity
rottlerin
modulated
Prior art date
Application number
PCT/US2000/027277
Other languages
French (fr)
Inventor
Gerald J. Gleich
Jennifer L. Bankers-Fulbright
Scott O'grady
Original Assignee
Mayo Foundation For Medical Education And Research
Regents Of The University Of Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22574446&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2001028543(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mayo Foundation For Medical Education And Research, Regents Of The University Of Minnesota filed Critical Mayo Foundation For Medical Education And Research
Priority to EP00968629A priority Critical patent/EP1233765A1/en
Priority to AU78513/00A priority patent/AU7851300A/en
Priority to CA002387786A priority patent/CA2387786A1/en
Priority to JP2001531373A priority patent/JP2003512321A/en
Publication of WO2001028543A1 publication Critical patent/WO2001028543A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • PKC protein kinase C
  • the , ⁇ legal ⁇ 2 and ⁇ isoforms are Ca 2+ , phospholipid- and diacylglycerol-dependent and represent the classical isoforms of PKC, whereas the other isoforms are activated by phospholipid and diacylglycerol but are not dependent on Ca 2+ (House et al. Science, 23_&, 1726 (1987)).
  • U.S. Patent Application Serial Number 08/985,613 discloses the use of a sulfonylurea receptor (SUR) binding agent to treat IL-5 mediated pathologies.
  • SUR sulfonylurea receptor
  • This application also discloses a method for inhibiting cytokine- induced eosinophil survival or activation with a sulfonylurea receptor binding agent, optionally in combination with one or more topical anesthetics and/or glucocorticoids.
  • the application also discloses a method for treating a disease mediated by ' IL-5 with an agent that is able to modify (e.g., block) ATP- dependent potassium channels, or a protein with which an ATP-dependent potassium channel interacts (such as a SUR). dependent potassium channels, or a protein with which an ATP-dependent potassium channel interacts (such as a SUR).
  • the present invention provides a method to treat an eosinophil-associated pathology in a mammal, comprising modulating the activity of PKC ⁇ in said mammal.
  • PKC ⁇ modulation is not achieved by administering lidocaine or other topical anaesthetics as described in U.S. Patent Nos. 5,510,339, 5,631,267 and 5,837,713, supra.
  • Figure 1 illustrates the specific binding of varying concentrations of lidocaine to both high and low density PKC ⁇ surfaces.
  • Figure 2 illustrates the inhibition of eosinophil superoxide production by the PKC ⁇ -selective blocker rottlerin.
  • Figure 3 illustrates the inhibition of eosinophil degranulation by rottlerin.
  • hypersensitivity diseases and conditions associated with elevated levels of eosinophil activation and accumulation are amenable to treatment by the present therapy.
  • These conditions include, but are not limited to, nasal inflammation, conjunctivitis, chronic eosinophilic pneumonia, allergic rhinitis, allergic sinusitis, allergic gastroenteropathy, eosinophilic gastroenteritis, atopic dermatitis, bullous pemphigoid, episodic angioedema associated with eosinophilia, ulcerative colitis, inflammatory bowel disease, vernal conjunctivitis, giant papillary conjunctivitis, and allergic conjunctivitis.
  • PCK ⁇ activity can be modulated in a mammal (i.e., increased or decreased with respect to the level that would have existed in said mammal in the absence of intervention) using any suitable manner known in the art.
  • PCK ⁇ activity can be modulated by administering an effective amount of a chemical agent that acts upon PKC ⁇ (e.g., an inhibitor), such as the specific inhibitor of the PKC ⁇ isozyme, rottlerin (CAS Registry No. 82-08-6), also known as mallotoxin.
  • Rottlerin is available from commercial sources, including R.B.I. (Natick, MA., U.S.A.) and Calbiochem (California, U.S.A.).
  • DEX dexniguldipine hydrochloride
  • EPO erythropoietin
  • PKC ⁇ protein kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinase kinas
  • human recombinant PKC ⁇ protein is also commercially available (BioMol Cat. No. SE-147).
  • DNA encoding PKC ⁇ can be used to alter the amount of PKC ⁇ in a cell.
  • DNA encoding any protein which interacts with PKC ⁇ , so as to modulate its activity (e.g., inhibit or increase its activity), is also envisioned.
  • DNA encoding PKC ⁇ , or a PKC ⁇ modulating protein can be readily introduced into host cells (e.g., mammalian, bacterial, yeast or insect cells) by transfection with an expression vector comprising DNA encoding PKC ⁇ , a PKC ⁇ modulating protein, or comprising DNA complementary to DNA encoding PKC ⁇ or a PKC ⁇ modulating protein.
  • host cells e.g., mammalian, bacterial, yeast or insect cells
  • an expression vector comprising DNA encoding PKC ⁇ , a PKC ⁇ modulating protein, or comprising DNA complementary to DNA encoding PKC ⁇ or a PKC ⁇ modulating protein.
  • This can be done by any procedure useful for the introduction into a particular cell (e.g., physical or biological methods), to yield a transformed cell having the recombinant DNA stably integrated into its genome, so that the DNA molecules, sequences, or segments, of the present invention are expressed by the host cell, as described by Sambrook et al., Molecular Cloning: A Laboratory
  • Physical methods to introduce a preselected DNA into a host cell include calcium phosphate precipitation, lipofection, particle bombardment, microinjection, electroporation, and the like.
  • Biological methods to introduce the DNA of interest into a host cell include the use of DNA and RNA viral vectors.
  • the main advantage of physical methods is that they are not associated with pathological or oncogenic processes of viruses. However, they are less precise, often resulting in multiple copy insertions, random integration, disruption of foreign and endogenous gene sequences, and unpredictable expression. For mammalian gene therapy, it is desirable to use an efficient means of precisely inserting a single copy gene into the host genome.
  • Viral vectors and especially retroviral vectors, have become the most widely used method for inserting genes into mammalian cells, such as human cells.
  • Other viral vectors can be derived from poxviruses, herpes simplex virus I, adenoviruses and adeno-associated viruses, and the like.
  • Antisense technology can also be used to alter the expression of PKC ⁇ in a mammal, for example, by administering to the mammal an effective amount of "antisense” mRNA transcripts or antisense oligonucleotides that encode PKC ⁇ which, when expressed from an expression cassette in a host cell, can alter PKC ⁇ expression.
  • antisense means a sequence of nucleic acid which is the reverse complement of at least a portion of a RNA or DNA molecule that codes for PKC ⁇ .
  • the introduced nucleic acid may be useful to modulate the expression of PKC ⁇ in mammals with an eosinophil-associated indication.
  • the administration of an expression vector encoding PKC ⁇ peptide may increase the PKC ⁇ activity and thus be efficacious for diseases which are characterized by decreased levels of PKC ⁇ .
  • the administration of an expression vector comprising antisense PKC ⁇ sequences may be useful to prevent or treat a disorder associated with increased PKC ⁇ expression.
  • a dominant-negative mutant of PKC ⁇ may also specifically inhibit PKC ⁇ expression.
  • Modulation of PKC ⁇ activity by the administration of antibodies which specifically react with PKC ⁇ is also contemplated.
  • An anti-PKC ⁇ antibody is commercially available from BioMol (Cat. No. S A- 148). The invention will now be illustrated by the following non- limiting examples.
  • Sensor chip CM5 (available from BIACORE AB, Uppsala, Sweden) was the surface of choice for this assay since it provides a versatile, flexible, robust surface which has high binding capacity and allows immobilization through primary amine coupling. Use of this surface in conjunction with a BIACORE® 2000 (BIACORE AB, Uppsala, Sweden) allows multi-channel analysis of four independent sensor surfaces termed flow cells.
  • HBS-N (0.01 M HEPES pH 7.4, 0.15 M NaCl) buffer was degassed and filtered prior to use and employed as running buffer throughout these experiments. This buffer was employed in order to avoid any possible detergent effects on binding interactions.
  • PKC ⁇ was diluted to 20 ⁇ g/ml in 10 mM Sodium Acetate, pH 4.5, using standard amine coupling procedures. The surface was derivatized through injection of a 1 : 1 EDC NHS mixture for 7 minutes, followed by injection of PKC ⁇ , followed by blocking of remaining activated carboxyl groups by 1 M ethanolamine, pH 8.5. The flow rate throughout was 10 ⁇ l/min. Low-density and high-density surfaces were prepared by controlled PKC ⁇ injections (6176.0 R.U.s and 15968.0 R.U.s respectively). A control surface was also prepared by exposing a separate flow cell to the activation and blocking steps.
  • Lidocaine hydrochloride was dissolved in running buffer (HBS-N) and this stock solution diluted to concentrations of 5 ⁇ g/ml, 10 ⁇ g/ml, 25 ⁇ g/ml and 40 ⁇ g/ml. These solutions were then injected over prepared surfaces at a flow rate of 20 ⁇ l/min for two minutes ( Figure 1).
  • PKC ⁇ coupled to the sensor chip surface, remained active to the binding of lidocaine following the immobilization procedure.
  • Two different surface densities of PKC ⁇ were employed to show that binding of lidocaine to PKC ⁇ was specific. Comparison to the control surface also discriminates between bulk refractive index changes and specific binding interactions. This data demonstrates that lidocaine binds PKC ⁇ .
  • Rottlerin a selective blocker of PKC ⁇ , was found to act like lidocaine by blocking superoxide production and inhibiting the activation of eosinophils.
  • Inhibitors were added immediately before stimulation unless otherwise noted.
  • a stock solution of rottlerin (Calbiochem) was diluted in HBSS so that the final concentration of DMSO or EtOH was less than 0.5%.
  • the rate of eosinophil superoxide production was calculated using the linear part of the superoxide production curve (usually 20 to 50 minutes following IL-5 stimulation) and is presented as nanomoles of superoxide produced per minute (Figure 2).
  • Supernatants from the superoxide assays were stored at -20°C and the degree of degranulation (EDN release) was assayed by RIA as described (Abu-Ghazaleh et al., J. Immunol.. 142. 2393-2400 (1989)) ( Figure 3).
  • PKC ⁇ -selective blocker inhibited the rate of superoxide production and magnitude of degranulation in a concentration- dependent manner, with IC 50 values (0.7 ⁇ M and 0.6 ⁇ M respectively) for rottlerin consistent with inhibition of PKC ⁇ catalytic activity (3-6 ⁇ M).
  • IC 50 values 0.7 ⁇ M and 0.6 ⁇ M respectively
  • PKC ⁇ likely plays a central role in the regulation of NADPH oxidase activity and degranulation in eosinophils.
  • agents that modulate the activity of PKC ⁇ are useful to treat diseases wherein activation of eosinophils is implicated (e.g., hypersensitivity diseases such as asthma).

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides methods to treat diseases associated with eosinophil activation, such as hypersensitivity diseases or conditions (e.g., asthma), by administrating an agent which modulates PKCδ activity.

Description

TREATMENT OF EOSTNOPHT ASSOCIATED PATHOT GTES BY MODULATING PKC-rielta ACTTVTTY
Background of the Invention Protein kinases play a critical role in cellular development, differentiation and transformation. One of the largest gene families of non- receptor serine-threonine protein kinases is protein kinase C (PKC). Since the discovery of PKC more than a decade ago, a multitude of physiological signaling mechanisms have been ascribed to the enzyme. The PKC gene family consists presently of 11 genes which are divided into four subgroups: 1) classical PKCα, Pi, β2 CPt and β2 are alternately spliced forms of the same gene) and γ; 2) novel PKCδ, e, η, and θ; 3) atypical PKCζ, λ, η and i ; and 4) PKCμ. The , β„ β2 and γ isoforms are Ca2+, phospholipid- and diacylglycerol-dependent and represent the classical isoforms of PKC, whereas the other isoforms are activated by phospholipid and diacylglycerol but are not dependent on Ca2+ (House et al. Science, 23_&, 1726 (1987)).
U.S. Patent Numbers 5,510,339 and 5,631,267 disclose the use of topical anesthetics, such as lidocaine and the like, to treat bronchial asthma and other eosinophil associated hypersensitivity diseases. Additionally, U.S. Patent Number 5,837,713 discloses the use of a synergistic combination of a topical anesthetic and a glucocorticoid to treat eosinophil associated pathologies.
U.S. Patent Application Serial Number 08/985,613 discloses the use of a sulfonylurea receptor (SUR) binding agent to treat IL-5 mediated pathologies. This application also discloses a method for inhibiting cytokine- induced eosinophil survival or activation with a sulfonylurea receptor binding agent, optionally in combination with one or more topical anesthetics and/or glucocorticoids. The application also discloses a method for treating a disease mediated by'IL-5 with an agent that is able to modify (e.g., block) ATP- dependent potassium channels, or a protein with which an ATP-dependent potassium channel interacts (such as a SUR). dependent potassium channels, or a protein with which an ATP-dependent potassium channel interacts (such as a SUR).
Despite the above disclosures, there is a continuing need for methods to treat pathologies associated with eosinophil activation. In particular, there is a need for methods to treat eosinophil-associated pathologies such as hypersensitivity diseases or conditions (e.g., asthma) utilizing novel pathways.
Summary of the Invention
Applicant has discovered that compounds that inhibit the activity of PKCδ are useful to treat diseases associated with eosinophil activation, such as hypersensitivity diseases or conditions (e.g., asthma). Accordingly, the present invention provides a method to treat an eosinophil-associated pathology in a mammal, comprising modulating the activity of PKCδ in said mammal. Preferably, PKCδ modulation is not achieved by administering lidocaine or other topical anaesthetics as described in U.S. Patent Nos. 5,510,339, 5,631,267 and 5,837,713, supra.
Brief Description of the Figures
Figure 1 illustrates the specific binding of varying concentrations of lidocaine to both high and low density PKCδ surfaces.
Figure 2 illustrates the inhibition of eosinophil superoxide production by the PKCδ-selective blocker rottlerin.
Figure 3 illustrates the inhibition of eosinophil degranulation by rottlerin.
Detailed Description of the Invention
In addition to asthma, hypersensitivity diseases and conditions associated with elevated levels of eosinophil activation and accumulation are amenable to treatment by the present therapy. These conditions include, but are not limited to, nasal inflammation, conjunctivitis, chronic eosinophilic pneumonia, allergic rhinitis, allergic sinusitis, allergic gastroenteropathy, eosinophilic gastroenteritis, atopic dermatitis, bullous pemphigoid, episodic angioedema associated with eosinophilia, ulcerative colitis, inflammatory bowel disease, vernal conjunctivitis, giant papillary conjunctivitis, and allergic conjunctivitis.
According to the invention, PCKδ activity can be modulated in a mammal (i.e., increased or decreased with respect to the level that would have existed in said mammal in the absence of intervention) using any suitable manner known in the art. For example, PCKδ activity can be modulated by administering an effective amount of a chemical agent that acts upon PKCδ (e.g., an inhibitor), such as the specific inhibitor of the PKCδ isozyme, rottlerin (CAS Registry No. 82-08-6), also known as mallotoxin. Rottlerin is available from commercial sources, including R.B.I. (Natick, MA., U.S.A.) and Calbiochem (California, U.S.A.). Other suitable chemical agents include dexniguldipine hydrochloride (DEX), which may affect PKCδ expression in cells (Proc. Annu. Meet. Am. Assoc. Cancer Res.. 36. A2598 (1995)). In addition, estrogen and erythropoietin (EPO) have also been reported to modulate PKCδ expression (Shanmugam et al, Mol. Cell. Endocrinology. 148. 109-118 (1999) and Cooper et al., Proc. Annu. Meet. Am. Assoc. Cancer Res.. 38, A2506 (1997)).
Other methods to regulate the cellular expression of PKCδ can also be employed, such as gene therapy. The complete nucleotide coding sequence of PKCδ is available (see GenBank Accession No.: 5453969).
Furthermore, human recombinant PKCδ protein is also commercially available (BioMol Cat. No. SE-147). DNA encoding PKCδ can be used to alter the amount of PKCδ in a cell. Alternatively, DNA encoding any protein which interacts with PKCδ, so as to modulate its activity (e.g., inhibit or increase its activity), is also envisioned.
DNA encoding PKCδ, or a PKCδ modulating protein, can be readily introduced into host cells (e.g., mammalian, bacterial, yeast or insect cells) by transfection with an expression vector comprising DNA encoding PKCδ, a PKCδ modulating protein, or comprising DNA complementary to DNA encoding PKCδ or a PKCδ modulating protein. This can be done by any procedure useful for the introduction into a particular cell (e.g., physical or biological methods), to yield a transformed cell having the recombinant DNA stably integrated into its genome, so that the DNA molecules, sequences, or segments, of the present invention are expressed by the host cell, as described by Sambrook et al., Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY (1989). Physical methods to introduce a preselected DNA into a host cell include calcium phosphate precipitation, lipofection, particle bombardment, microinjection, electroporation, and the like. Biological methods to introduce the DNA of interest into a host cell include the use of DNA and RNA viral vectors. The main advantage of physical methods is that they are not associated with pathological or oncogenic processes of viruses. However, they are less precise, often resulting in multiple copy insertions, random integration, disruption of foreign and endogenous gene sequences, and unpredictable expression. For mammalian gene therapy, it is desirable to use an efficient means of precisely inserting a single copy gene into the host genome. Viral vectors, and especially retroviral vectors, have become the most widely used method for inserting genes into mammalian cells, such as human cells. Other viral vectors can be derived from poxviruses, herpes simplex virus I, adenoviruses and adeno-associated viruses, and the like.
Antisense technology can also be used to alter the expression of PKCδ in a mammal, for example, by administering to the mammal an effective amount of "antisense" mRNA transcripts or antisense oligonucleotides that encode PKCδ which, when expressed from an expression cassette in a host cell, can alter PKCδ expression. As used herein, the term "antisense" means a sequence of nucleic acid which is the reverse complement of at least a portion of a RNA or DNA molecule that codes for PKCδ. The introduction of PKCδ sense or antisense nucleic acid into a cell ex vivo or in vivo can result in a molecular genetic-based therapy directed to controlling the expression of PKCδ. Thus, the introduced nucleic acid may be useful to modulate the expression of PKCδ in mammals with an eosinophil-associated indication. For example, the administration of an expression vector encoding PKCδ peptide may increase the PKCδ activity and thus be efficacious for diseases which are characterized by decreased levels of PKCδ. Likewise, the administration of an expression vector comprising antisense PKCδ sequences may be useful to prevent or treat a disorder associated with increased PKCδ expression.
In addition, the administration of a dominant-negative mutant of PKCδ may also specifically inhibit PKCδ expression. (Jain et al., J. Biol. Chem.. 274. 24392-24400 (1999)). Modulation of PKCδ activity by the administration of antibodies which specifically react with PKCδ is also contemplated. An anti-PKCδ antibody is commercially available from BioMol (Cat. No. S A- 148). The invention will now be illustrated by the following non- limiting examples.
Example 1
The following procedure was carried out to assess the ability of lidocaine to bind PKCδ.
Materials and Methods. Sensor chip CM5 (available from BIACORE AB, Uppsala, Sweden) was the surface of choice for this assay since it provides a versatile, flexible, robust surface which has high binding capacity and allows immobilization through primary amine coupling. Use of this surface in conjunction with a BIACORE® 2000 (BIACORE AB, Uppsala, Sweden) allows multi-channel analysis of four independent sensor surfaces termed flow cells.
HBS-N (0.01 M HEPES pH 7.4, 0.15 M NaCl) buffer was degassed and filtered prior to use and employed as running buffer throughout these experiments. This buffer was employed in order to avoid any possible detergent effects on binding interactions.
All experiments were carried out at 25°C and all reagents were used as supplied.
Surface Preparation. PKCδ was diluted to 20 μg/ml in 10 mM Sodium Acetate, pH 4.5, using standard amine coupling procedures. The surface was derivatized through injection of a 1 : 1 EDC NHS mixture for 7 minutes, followed by injection of PKCδ, followed by blocking of remaining activated carboxyl groups by 1 M ethanolamine, pH 8.5. The flow rate throughout was 10 μl/min. Low-density and high-density surfaces were prepared by controlled PKCδ injections (6176.0 R.U.s and 15968.0 R.U.s respectively). A control surface was also prepared by exposing a separate flow cell to the activation and blocking steps.
Binding Interactions. Lidocaine hydrochloride was dissolved in running buffer (HBS-N) and this stock solution diluted to concentrations of 5 μg/ml, 10 μg/ml, 25 μg/ml and 40 μg/ml. These solutions were then injected over prepared surfaces at a flow rate of 20 μl/min for two minutes (Figure 1).
Results
PKCδ. coupled to the sensor chip surface, remained active to the binding of lidocaine following the immobilization procedure. Two different surface densities of PKCδ were employed to show that binding of lidocaine to PKCδ was specific. Comparison to the control surface also discriminates between bulk refractive index changes and specific binding interactions. This data demonstrates that lidocaine binds PKCδ.
Example 2
In the following assay, Rottlerin, a selective blocker of PKCδ, was found to act like lidocaine by blocking superoxide production and inhibiting the activation of eosinophils.
Materials and Methods. Superoxide assays were performed in HBSS buffer supplemented with 10 mM HEPES. Cytochrome C was used to detect the production of extracellular superoxide formation as previously described (Bankers-Fulbright et al., J. Immunol.. 160. 5546-5553 (1998)).
Inhibitors were added immediately before stimulation unless otherwise noted. A stock solution of rottlerin (Calbiochem) was diluted in HBSS so that the final concentration of DMSO or EtOH was less than 0.5%. The rate of eosinophil superoxide production was calculated using the linear part of the superoxide production curve (usually 20 to 50 minutes following IL-5 stimulation) and is presented as nanomoles of superoxide produced per minute (Figure 2). Supernatants from the superoxide assays were stored at -20°C and the degree of degranulation (EDN release) was assayed by RIA as described (Abu-Ghazaleh et al., J. Immunol.. 142. 2393-2400 (1989)) (Figure 3).
Results
The PKCδ-selective blocker, rottlerin, inhibited the rate of superoxide production and magnitude of degranulation in a concentration- dependent manner, with IC50 values (0.7 μM and 0.6 μM respectively) for rottlerin consistent with inhibition of PKCδ catalytic activity (3-6 μM). Thus, PKCδ likely plays a central role in the regulation of NADPH oxidase activity and degranulation in eosinophils. Accordingly, Applicant has discovered that agents that modulate the activity of PKCδ are useful to treat diseases wherein activation of eosinophils is implicated (e.g., hypersensitivity diseases such as asthma).
All publications, patents, and patent documents are incorporated by reference herein, as though individually incorporated by reference. The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention.

Claims

WHAT IS CLAIMED IS:
1. The use of a chemical agent that modifies PKCδ activity to prepare a medicament for treating a hypersensitivity disease or condition in a mammal, provided the agent is not lidocaine or another topical anesthetic.
2. The use of claim 1, wherein the agent inhibits PKCδ activity.
3. The use of claim 1, wherein the agent is rottlerin, antisense mRNA, an antisense oligonucleotide, or an antibody.
4. The use of claim 1, wherein the agent is DNA.
5. The use of claim 1 , wherein the agent is not rottlerin.
6. The use of claim 1, wherein the agent is rottlerin.
7. The use of claim 1, wherein the agent is antisense mRNA.
8. The use of claim 1, wherein the agent is an antisense oligonucleotide.
9. The use of claim 1, wherein the agent is an antibody.
10. The use of claim 1 , wherein the hypersensitivity disease or condition is asthma.
11. A therapeutic method for treating a hypersensitivity disease or condition in a mammal comprising modulating PKCδ activity in the mammal; wherein PKCδ activity is not modulated by the administration of lidocaine or another topical anesthetic.
12. The method of claim 11 , wherein the PKCδ activity is modulated by administration of an effective amount of a chemical agent.
13. The method of claim 12, wherein the PKCδ activity is inhibited.
14. The method of claim 12, wherein the chemical agent is rottlerin.
15. The method of claim 11 or 12, wherein the chemical agent is not rottlerin.
16. The method of claim 11 wherein the PKCδ activity is modulated by gene therapy.
17. The method of claim 11 , wherein the PKCδ activity is modulated by the administration of antisense mRNA, or a fragment thereof, which specifically binds PKCδ.
18. The method of claim 11, wherein the PKCδ activity is modulated by the administration of antisense oligonucleotide, or fragment thereof, which specifically binds PKCδ.
19. The method of claim 11 , wherein the PKCδ activity is modulated by the administration of antibodies which specifically react with PKCδ.
20. The method of any one of claims 11-19 wherein the hypersensitivity disease or condition is asthma.
PCT/US2000/027277 1999-10-15 2000-10-03 TREATMENT OF EOSINOPHIL ASSOCIATED PATHOLOGIES BY MODULATING PKC-δ ACTIVITY WO2001028543A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00968629A EP1233765A1 (en) 1999-10-15 2000-10-03 TREATMENT OF EOSINOPHIL ASSOCIATED PATHOLOGIES BY MODULATING PKC-$g(d) ACTIVITY
AU78513/00A AU7851300A (en) 1999-10-15 2000-10-03 Treatment of eosinophil associated pathologies by modulating pkc-delta activity
CA002387786A CA2387786A1 (en) 1999-10-15 2000-10-03 Treatment of eosinophil associated pathologies by modulating pkc-.delta. activity
JP2001531373A JP2003512321A (en) 1999-10-15 2000-10-03 Treatment of eosinophil-related diseases by modulation of PKC-δ activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15987299P 1999-10-15 1999-10-15
US60/159,872 1999-10-15

Publications (1)

Publication Number Publication Date
WO2001028543A1 true WO2001028543A1 (en) 2001-04-26

Family

ID=22574446

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/027277 WO2001028543A1 (en) 1999-10-15 2000-10-03 TREATMENT OF EOSINOPHIL ASSOCIATED PATHOLOGIES BY MODULATING PKC-δ ACTIVITY

Country Status (5)

Country Link
EP (1) EP1233765A1 (en)
JP (1) JP2003512321A (en)
AU (1) AU7851300A (en)
CA (1) CA2387786A1 (en)
WO (1) WO2001028543A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004084889A1 (en) * 2003-03-28 2004-10-07 Pfizer Inc. Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons
WO2005107789A1 (en) * 2004-04-30 2005-11-17 The Board Of Trustees Of The Leland Stanford Junior University Use of delta pkc peptides for modulation of reactive oxigen species
US7563772B2 (en) 2005-01-04 2009-07-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of increasing cerebral blood flow

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004918A2 (en) * 1988-10-25 1990-05-17 Wake Forest University Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
US5470860A (en) * 1991-12-13 1995-11-28 Byk Gulden Lomberg Chemische Fabrik Gmbh 1,4-dihydropyridines for use in the treatment of dermatoses
US5510339A (en) * 1993-02-02 1996-04-23 Mayo Foundation For Medical Education And Research Method for the treatment of bronchial asthma by administration of topical anesthetics
WO1997038693A1 (en) * 1996-04-18 1997-10-23 Alcon Laboratories, Inc. Calcium channel blockers as human conjunctival mast cell degranulation inhibitors for treating ocular allergic conditions
US5922571A (en) * 1997-03-06 1999-07-13 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a protein kinase C homolog
WO1999046264A1 (en) * 1998-03-13 1999-09-16 Astrazeneca Ab New compounds
WO1999062537A1 (en) * 1998-06-04 1999-12-09 The Rockefeller University Methods and agents for modulating the immune response and inflammation involving monocyte and dendritic cell membrane proteins
WO2000070091A1 (en) * 1999-05-18 2000-11-23 Isis Pharmaceuticals, Inc. ANTISENSE OLIGONUCLEOTIDE MODULATION OF HUMAN PROTEIN KINASE C-δ EXPRESSION

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004918A2 (en) * 1988-10-25 1990-05-17 Wake Forest University Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
US5470860A (en) * 1991-12-13 1995-11-28 Byk Gulden Lomberg Chemische Fabrik Gmbh 1,4-dihydropyridines for use in the treatment of dermatoses
US5510339A (en) * 1993-02-02 1996-04-23 Mayo Foundation For Medical Education And Research Method for the treatment of bronchial asthma by administration of topical anesthetics
WO1997038693A1 (en) * 1996-04-18 1997-10-23 Alcon Laboratories, Inc. Calcium channel blockers as human conjunctival mast cell degranulation inhibitors for treating ocular allergic conditions
US5922571A (en) * 1997-03-06 1999-07-13 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a protein kinase C homolog
WO1999046264A1 (en) * 1998-03-13 1999-09-16 Astrazeneca Ab New compounds
WO1999062537A1 (en) * 1998-06-04 1999-12-09 The Rockefeller University Methods and agents for modulating the immune response and inflammation involving monocyte and dendritic cell membrane proteins
WO2000070091A1 (en) * 1999-05-18 2000-11-23 Isis Pharmaceuticals, Inc. ANTISENSE OLIGONUCLEOTIDE MODULATION OF HUMAN PROTEIN KINASE C-δ EXPRESSION

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BHEEKHAESCURA R.,CHANCE S.R. ET AL.: "Pharmacologic regulation of histamine release by the human recombinant histamine-releasing factor.", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 103, no. 5 part 1, May 1999 (1999-05-01), pages 937 - 943, XP000991205 *
KIM H.M.,KO S.G. ET AL.: "Interleukin-3 or immunoglobulin E promotes expression of protein kinase C delta gene in murine mast cells.", PHARMACOLOGICAL RESEARCH, vol. 40, no. 2, August 1999 (1999-08-01), pages 147 - 151, XP000991210 *
MODY V.D., MANGALAN S., PANDYA K.K. ET AL.: "Absorption of Herbinol - a polyherbal topical cream", JOURNAL OF PHARMACY TECHNOLOGY, vol. 10, no. 2, 1994, pages 71 - 74, XP000992187 *
MYERS J R ET AL: "Should supplemental estrogens be used as steroid-sparing agents in asthmatic women? [see comments].", CHEST, (1994 JUL) 106 (1) 318-9., XP000991209 *
SHANMUGAM MALATHY ET AL: "Regulation of protein kinase C delta by estrogen in the MCF-7 human breast cancer cell line.", MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 148, no. 1-2, 25 February 1999 (1999-02-25), pages 109 - 118, XP000991396, ISSN: 0303-7207 *
TANG Y ET AL: "Dexniguldipine hydrochloride, a protein kinase C-specific inhibitor, suppresses in vitro growth of human pancreatic and colon cancer cells.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 36, 1995, Eighty-sixth Annual Meeting of the American Association for Cancer Research;Toronto, Ontario, Canada; March 18-22, 1995, 1995, pages 436, XP000990227, ISSN: 0197-016X *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004084889A1 (en) * 2003-03-28 2004-10-07 Pfizer Inc. Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons
WO2005107789A1 (en) * 2004-04-30 2005-11-17 The Board Of Trustees Of The Leland Stanford Junior University Use of delta pkc peptides for modulation of reactive oxigen species
US7563772B2 (en) 2005-01-04 2009-07-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of increasing cerebral blood flow
US8492348B2 (en) 2005-01-04 2013-07-23 The Board Of Trustees Of The Leland Stanford Junior University Methods of increasing cerebral blood flow

Also Published As

Publication number Publication date
AU7851300A (en) 2001-04-30
EP1233765A1 (en) 2002-08-28
JP2003512321A (en) 2003-04-02
CA2387786A1 (en) 2001-04-26

Similar Documents

Publication Publication Date Title
Christoph et al. Silencing of vanilloid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo
Nassal et al. Challenges and opportunities for therapeutic targeting of calmodulin kinase II in heart
PT2029746E (en) Compositions and methods for sirna inhibition of angiogenesis
EP1877556A2 (en) USE OF ANTI-TNF OR ANTI-ILl RNAI TO SUPPRESS PRO- INFLAMMATORY CYTOKINE ACTIONS LOCALLY TO TREAT PAIN
JP2010500025A (en) Methods and sequences for suppressing primate Huntington gene expression in vivo
Chu et al. Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human glioma
KR20100127880A (en) Compositions and use of epas1 inhibitors
BR112019012825A2 (en) compositions and methods for treating alpha-1 antitrypsin deficiency
Denham et al. Directed antisense therapy confirms the role of protein kinase C–α in the tumorigenicity of pancreatic cancer
US20220218682A1 (en) Compositions and methods for treating cancer
WO2018140934A1 (en) Compositions and methods for hemoglobin production
Li et al. Major signaling pathways and key mediators of macrophages in acute kidney injury
Mattson et al. Anti-apoptotic actions of cycloheximide: blockade of programmed cell death or induction of programmed cell life?
US11077110B2 (en) Compositions and methods for treating and preventing metabolic disorders
WO2001028543A1 (en) TREATMENT OF EOSINOPHIL ASSOCIATED PATHOLOGIES BY MODULATING PKC-δ ACTIVITY
US11130950B2 (en) Methods and pharmaceutical compositions for the treatment of cystic fibrosis
US20190062756A1 (en) Compounds for modulating fc-epsilon-ri-beta expression and uses thereof
Cahill et al. Stable silencing of SNAP-25 in PC12 cells by RNA interference
WO2016036886A1 (en) Compositions and methods for treating fibrosing disorders and cancer
Traister et al. Inflammatory cytokine regulation of transgene expression in human fibroblast‐like synoviocytes infected with adeno‐associated virus
EP4155402A1 (en) Modulation of microrna-335 for the treatment of sodium channelopathies
US11987793B2 (en) Compositions and methods for prevention of bladder fibrosis
WO2023152369A1 (en) Nucleic acid mir-9 inhibitor for the treatment of cystic fibrosis
Yellenki Role of Diacylglycerol kinase alpha (DGKA) as a therapeutic target in Glioblastoma (GB)
US20230285440A1 (en) Compositions and methods for treatment of sepsis-related disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2001 531373

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2387786

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000968629

Country of ref document: EP

Ref document number: 78513/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 518719

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 2000968629

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000968629

Country of ref document: EP